drugset
drugset / Trial / NCT06851559

A Study in Adult Participants With EoE to Evaluate Vonoprazan 20 mg Compared to Placebo After 12 Weeks and to Evaluate Vonoprazan 20 mg Up to 24 Weeks

NCT06851559 ↗

Phase 2 Active not recruiting 95 enrolled Phathom Pharmaceuticals, Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

The primary objective of this study is to assess the efficacy of vonoprazan 20 mg once daily (QD) compared to placebo QD in the number of participants with a peak eosinophilic histologic response \<15 eosinophils per high-power field (eos/hpf) after 12 weeks of therapy.

Timeline

Start
2025-10-30
Primary completion
2026-10
Completion
2027-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Vonoprazan Other / unclassified 20 mg Oral

Indications

eosinophilic esophagitis